Glofitamab for relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in patients who are not candidates for autologous stem cell transplant

Agency for Care Effectiveness (ACE)
Record ID 32018016075
English
Details
Project Status: Completed
Year Published: 2026
URL for published report: https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/glofitamab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-not-otherwise-specified-in-patients-who-are-not-candidates-for-autologous-stem-cell-transplant/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • Lymphoma, Large B-Cell, Diffuse
  • Antibodies, Bispecific
Contact
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name: ACE_HTA@moh.gov.sg
Contact Email: ACE_HTA@moh.gov.sg
Copyright: Agency for Care Effectiveness (ACE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.